New York State Teachers Retirement System Lowers Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

New York State Teachers Retirement System reduced its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 5.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,311 shares of the biotechnology company's stock after selling 3,400 shares during the period. New York State Teachers Retirement System owned approximately 0.12% of United Therapeutics worth $17,051,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in UTHR. Signaturefd LLC grew its stake in United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after buying an additional 30 shares in the last quarter. Parallel Advisors LLC raised its position in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock valued at $385,000 after buying an additional 30 shares in the last quarter. Anchor Investment Management LLC lifted its holdings in shares of United Therapeutics by 12.0% during the 4th quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 30 shares during the last quarter. Great Lakes Advisors LLC grew its position in United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after acquiring an additional 31 shares in the last quarter. Finally, Florida Financial Advisors LLC grew its position in United Therapeutics by 6.2% in the fourth quarter. Florida Financial Advisors LLC now owns 822 shares of the biotechnology company's stock worth $290,000 after acquiring an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analyst Ratings Changes

UTHR has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research note on Thursday, May 1st. Bank of America decreased their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Cantor Fitzgerald began coverage on United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price for the company. UBS Group cut their target price on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday. Finally, Morgan Stanley increased their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the company an "equal weight" rating in a research report on Thursday, May 1st. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $386.15.

Insider Buying and Selling

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares of the company's stock, valued at $5,613,606.40. This represents a 13.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, June 26th. The stock was sold at an average price of $285.70, for a total value of $3,142,700.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $10,508,331.70. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 80,681 shares of company stock valued at $23,951,939 over the last ninety days. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 1.5%

Shares of NASDAQ UTHR opened at $295.22 on Thursday. The firm's fifty day moving average is $301.18 and its 200 day moving average is $323.65. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The company has a market cap of $13.32 billion, a price-to-earnings ratio of 11.78, a PEG ratio of 6.37 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $6.17 earnings per share. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.